Navigation Links
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
Date:7/22/2009

. Further, Vyvanse treatment was associated with significant efficacy as measured by both subjective (SKAMP-D and SKAMP-A) and objective (PERMP) assessments from the first time point (1.5 hours) through the last time point (13 hours) assessed during the classroom day, and at all time points in between (2.5, 5.0, 7.5, 10.0, and 12.0 hours).

Safety was also evaluated during the study. The adverse event profile for Vyvanse was similar to other currently marketed stimulants. The most frequently reported adverse events (greater than or equal to 10 percent) in the dose-optimization phase for patients taking Vyvanse were decreased appetite, insomnia, headache, irritability, upper abdominal pain, and affect lability.

Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg. To date, more than 6 million Vyvanse prescriptions have been filled, bringing the current US market share to over 12 percent based on weekly branded prescription volume. Additionally, Shire has executed agreements with 10 of Shire's top 11 managed care organizations (MCOs) to cover Vyvanse in a preferred formulary position.

Vyvanse is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.

Additional information about Vyvanse and Full Prescribing Information, including Medication Guide, are available at www.vyvanse.com.

About VYVANSE


'/>"/>
SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 BioStructures, ... it has hit a milestone of 4,000 implantations ... FDA 510(k) cleared in early 2014 as a ... posterolateral spine fusion procedures.  This is a distinguished ... less than 6% of new synthetic products have ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
(Date:7/28/2015)... Israel , July 28, 2015 /PRNewswire/ ... regenerative medicine company utilizing its proprietary plant-based rhCollagen ... Shomrat Shurtz has been appointed Senior Director of ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... experience in marketing, regulatory and business strategy. Prior ...
(Date:7/27/2015)... July 27, 2015  Amgen (NASDAQ: AMGN ) ... financial results on Thursday, July 30, 2015, after the ... be followed by a conference call with the investment ... from Amgen will be Robert A. Bradway , ... Amgen,s senior management team. Live audio of ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
... 28 Techne Corporation (Nasdaq: TECH ) announced ... dividend of $0.25 per share for the quarter ended March ... 22, 2009 to all common shareholders of record on May ... the Board of Directors on a quarterly basis.Techne,s Board of ...
... for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand ... 28 Cepheid (Nasdaq: CPHD ) today ... Patient Management in the Era of Rapid Diagnostics ," ... Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking ...
Cached Biology Technology:PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 3Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 4Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 5
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... LA JOLLA, CA January 4, 2011 Researchers ... Cornell University have produced a long-lasting anti-cocaine immunity in mice ... the common cold virus with a particle that mimics cocaine. ... advanced online edition of Molecular Therapy , the researchers ...
... humans during sleep, a University of Colorado team has ... one night of sleep is the equivalent of walking ... will help researchers further understand one of the important ... Kenneth Wright. Wright, who led the study, said the ...
... a foundation of marine biodiversity research laid by the ... leaders from academia, government, and ocean-focused funding agencies are ... to capitalize on Canada,s emergence as a global leader ... Canada,s world-class marine science infrastructure to plan for sustainable ...
Cached Biology News:Team creates novel vaccine that produces strong immunity against cocaine high 2Team creates novel vaccine that produces strong immunity against cocaine high 3Team creates novel vaccine that produces strong immunity against cocaine high 4Metabolic cost of human sleep deprivation quantified by University of Colorado team 2Metabolic cost of human sleep deprivation quantified by University of Colorado team 3Canadian marine biodiversity scientists forging strategy for sustainable ocean use 2Canadian marine biodiversity scientists forging strategy for sustainable ocean use 3
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic gel acid stain has also found ... bandshift assays. One mL stains 100 minigels. A ...
Synonym: modified Grace's Insect medium...
... is a 12 amino acid synthetic peptide whose sequence is ... peptide is (amino to carboxy terminus): C - S(338) ... - Q - V - A - P - A(348). ... control experiments with the polyclonal antibody that reacts with this ...
... The proteomic service includes protein separation ... using the PDQuest software package from ... mass spectrometry. In order to meet ... preparation, data analysis and format of ...
Biology Products: